Abstract | BACKGROUND: The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. MATERIALS AND METHODS: Gene expression analysis was performed using Affymetrix GeneChip human genome U133 Plus 2.0 arrays. Changes in protein expression were evaluated using 2D polyacrylamide gels followed by LCMS/MS. RESULTS: CONCLUSION:
|
Authors | Natalia A Ignatenko, Hagit F Yerushalmi, Ritu Pandey, Karen L Kachel, David E Stringer, Laurence J Marton, Eugene W Gerner |
Journal | Cancer genomics & proteomics
(Cancer Genomics Proteomics)
2009 May-Jun
Vol. 6
Issue 3
Pg. 161-75
ISSN: 1109-6535 [Print] Greece |
PMID | 19487545
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- (N(1),N(12))bis(ethyl)-6,7-dehydrospermine
- Antineoplastic Agents
- Protein Synthesis Inhibitors
- Proteins
- Spermine
|
Topics |
- Antineoplastic Agents
(chemistry, pharmacology)
- Colonic Neoplasms
(genetics, metabolism)
- Drug Screening Assays, Antitumor
- Gene Expression
(drug effects)
- Genes, Neoplasm
(drug effects)
- HCT116 Cells
- Humans
- Protein Synthesis Inhibitors
(pharmacology)
- Proteins
(genetics, metabolism)
- Spermine
(analogs & derivatives, pharmacology)
|